Selected publications

publications-bodyHere is a selection of our recent high impact publications. To view the full range from our expert scientists on staff profiles visit the staff page




Journal and date

Nicol SM, Sabbah S, Brulois KF, Jung JU, Bell AI, Hislop AD. (2016)

Primary B lymphocytes infected with KSHV can be expanded in vitro and are recognized by LANA-specific CD4+ T cells. 

Journal of Virology.
DOI: 10.1128/JVI.02377-15.

Leonard SM, Pereira M, Roberts S, Cuschieri K, Nuovo G, San Cassia P, Athavale R, Young LS, Ganesan R, Woodman CB. (2016)

Evidence of disrupted high-risk human papillomavirus DNA in morphologically normal cervices of older women. 


Scientific Reports.
6:20847 DOI:10.1038/srep20847. 

Jayasooriya S, de Silva TI, Njie-jobe J, Sanyang C, Leese AM, Bell AI, McAulay KA, Yanchun P, Long HM, Dong T, Whittle HC, Rickinson AB, Rowland-Jones SL, Hislop AD*, Flanagan KL*. (2015)

*Joint senior author

Early virological and immunological events in asymptomatic Epstein-Barr virus infection in African children. 


PLoS Pathogens. 

Burns DM, Tierney R, Shannon-Lowe C, Croudace J, Inman C, Abbotts B, Nagra S, Fox CP, Chaganti S, Craddock C, Moss P, Rickinson AB, Rowe M and Bell AI. (2015)

Memory B cell reconstitution following allogeneic haematopoietic stem cell transplantation is an EBV-associated transformation event.  

126(25):2665-75. DOI: 10.1182/blood-2015-08-665000.

Tierney RJ, Nagra J, Rowe M, Bell AI and Rickinson AB. (2015)

The Epstein-Barr virus BamHI C promoter is not essential for B cell immortalisation in vitro but greatly enhances B cell growth transformation. 

 J Virol.
89: 2483-2493.

Paris C, Pentland I, Groves I, Roberts DC, Coleman N, Roberts S and Parish JL. (2015)

CCCTC-Binding Factor Recruitment to the Early Region of the Human Papillomavirus Type 18 Genome Regulates Viral Oncogene Expression. 

Journal of Virology.

Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD. (2015)

The immunology of Epstein-Barr virus-induced disease. 

Annual Reviews in Immunology.
33:787-821. DOI: 10.1146/annurev-immunol-032414-112326. 

Yap L-F, Velapasamy S, Lee H-M, Thavaraj S, Pathmanathan R, Wei W, Vrzalikova K, Khoo A, Tsao S-W, Paterson I, Taylor G, Dawson C, Murray PG. (2015)

Downregulation of LPA receptor 5 contributes to aberrant LPA signalling in EBV-associated nasopharyngeal carcinoma. 

 Journal of Pathology. 
235: 456-65.

Vockerodt M, Yap LF, Shannon-Lowe C, Curley H, Wei W, Vrzalikova K, Murray PG. (2015)

The Epstein-Barr virus and the pathogenesis of lymphoma.

Journal of Pathology.
235: 312-22.

Wilson GK, Farquhar MJ, Meredith L, Dhawan A, Mitry R, Balfe P, McKeating JA. (2015)

Permissivity of primary hepatocytes and hepatoma cell lines to support hepatitis C virus infection. 

Journal of General Virology.
96: 1369-73.

Quinn LL, Williams LR, White C, Forrest C, Zuo J, Rowe M. (2015)

The missing link in EBV immune evasion: the BDLF3 gene induces ubiquitination and downregulation of MHC class I and MHC class II. 

Journal of Virology.

Prescott, EL, Brimacombe, CL, Hartley, M, Bell, I, Graham, SV, Roberts, S. (2014) 

Human papillomavirus type 1 (HPV1) E1^E4 protein is a potent inhibitor of the serine-arginine (SR) protein kinase SRPK1 and inhibits phosphorylation of host SR proteins and of the viral transcription and replication regulator E2. 

Journal of Virology.
88:12599-611, DOI:10.1128/JVI.02029-14 Featured in Spotlight

Taylor GS, Jia H, Harrington K, Lee LW, Turner J, Ladell K, Price DA, Tanday M, Matthews J, Roberts C, Edwards C, McGuigan L, Hartley A, Wilson S, Hui EP, Chan AT, Rickinson AB, Steven NM. (2014) 

A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. 

Clinical Cancer Research.
20(19):5009-22. DOI: 10.1158/1078-0432.CCR-14-1122-T. 

Meredith LW, Farquhar MJ, Tarr AW, McKeating JA. (2014)

Type I interferon rapidly restricts infectious hepatitis C virus particle genesis.

60(6):1891-901. DOI: 10.1002/hep.27333.

Quinn LL, Zuo J, Abbott RJ, Shannon-Lowe C, Tierney RJ, Hislop AD*, Rowe M*. (2014)

Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle

PLoS Pathogens.
10:e1004322. *Joint senior author

Rowe M, Raithatha S, Shannon-Lowe C.(2014)

Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions. 

Journal of Virology. 88(20):12065-76.